CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,250 enrolled
Drug / intervention
COVID-19 Antibody testingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04448717
NCT04448717N/ACompleted
CompareCT.gov

Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in a Public School Population - a Population-based Observational Study to Inform Policy Making

University of Zurich·observational·Posted Jun 26, 2020·Updated Apr 3, 2025

In Brief

An observational study evaluating COVID-19 Antibody testing for SARS-CoV 2 and COVID-19. Completed, enrolled 4,250 participants across 1 site.

Detailed Summary

There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists. The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and risk factors in a representative cohort of children and adolescents in the canton of Zurich, Switzerland, shortly after re-opening of the school system and thereafter. The study also investigates antibodies to SARS-CoV-2 in parents of the children and school personnel.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV 2, COVID-19
CountriesSwitzerland
CollaboratorsSwiss School of Public Health (SSPH+)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 26, 2020
Enrollment StartJun 16, 2020
Primary CompletionJul 20, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.0 years ago

Interventions

COVID-19 Antibody testingother

COVID-19 Antibody testing in venous blood and/or saliva samples.